Comparative Pharmacology
Head-to-head clinical analysis: ALOXI versus ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOXI versus ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER.
ALOXI vs ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, inhibiting emetic reflex.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
8 mg IV or 0.15 mg/kg IV every 8 hours for 3 doses or 32 mg IV once over 15 minutes for prevention of chemotherapy-induced nausea, or 4 mg IV once over 2-5 minutes for prevention of postoperative nausea. IV infusion in D5W at concentrations up to 1 mg/mL.
None Documented
None Documented
Clinical Note
moderateRaloxifene + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Fluconazole
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life is approximately 3-6 hours in adults, but may be prolonged in elderly patients (up to 8 hours) and in patients with severe hepatic impairment (Child-Pugh class C: 15-32 hours).
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Approximately 5% of ondansetron is excreted unchanged in urine; the remainder undergoes extensive hepatic metabolism via CYP1A2, CYP2D6, and CYP3A4, with metabolites excreted in urine (about 44-60% of total dose) and feces (about 33-38%).
Category C
Category A/B
5-HT3 Antagonist
5-HT3 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Raloxifene."